Salt Lake City, January 10, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research facility in Los Angeles with two decades of experience in neurological...
News at CenExel
The Placebo-Control Reminder Script in Depression and Psychosis Trials: An Antidote for the Placebo and Nocebo Response
CenExel is proud to highlight the poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2020, Miami, FL. ABSTRACT Introduction: Depression and psychosis clinical trials share a crucial commonality of perpetually and...
Esketamine Receives Support from 2 FDA Committees
Esketamine, a drug developed by Johnson & Johnson for the treatment of depression has received support from two FDA committees. Final FDA approval is expected by March 2019. The drug has been approved for use in treatment resistant depression. From the...
Taming the Placebo Effect in Depression Clinical Trials: The Methodological Implementation of a Placebo-Control Reminder Script
CenExel is proud to highlight the poster presented at the Annual International Society for CNS Clinical Trials and Methodology (ISCTM) Meeting, February 2019, Washington, DC. ABSTRACT Introduction: Although the placebo effect continues to persist within depressive...
Depression Treatment Gaithersburg
Depression treatment Gaithersburg. If you are experiencing depression and no medications have really helped, maybe one of our trials will.
Depression Research Study Participants Needed
Depression research study participants needed to take part in several clinical research trials exploring the effects of rapastinel, esketamine, and ketamine like compounds. Generally, research participants for these trials should: Be diagnosed with major depression Be...